HUTCHMED (00013) will release clinical data at the 2024 ESMO Annual Meeting and 2024 WCLC.

HUTCHMED (00013) announced that they will present the latest and updated data from multiple studies of compounds developed by HUTCHMED at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, USA and the 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) in Barcelona, Spain. The results of the FLOWERS study will be presented at the 2024 WCLC. This is a double-arm, randomized, multicenter, Phase II prospective clinical trial evaluating the use of osimertinib alone or in combination with savolitinib for first-line treatment of late-stage non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations and mesenchymal-epithelial transition factor (MET) abnormalities. As of the data cutoff date of May 28, 2024, the median follow-up time was 8.2 months. With longer follow-up, patients receiving osimertinib in combination with savolitinib (Cohort 2, n=21) showed deeper and more durable disease responses compared to those receiving osimertinib alone (Cohort 1, n=23). The confirmed objective response rates (ORR) for Cohorts 1 and 2 were 60.9% and 90.5%, and disease control rates (DCR) were 87% and 95.2%, respectively. Progression-free survival (PFS) data is not mature yet, but a favorable trend towards the combination therapy was observed, with median PFS for Cohorts 1 and 2 being 9.3 months and 19.6 months, with maturity rates of 34.8% and 23.8%, respectively. The safety profiles of osimertinib alone and in combination with savolitinib were as expected, tolerable and manageable. Further analysis of the FRESCO-2 study of fruquintinib in metastatic colorectal cancer, the FRUTIGA gastric cancer study, savolitinib biomarker research in gastric cancer patients, and studies of fruquintinib and surufatinib initiated by researchers will be presented at the 2024 ESMO Annual Meeting.